EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] Clinical trial design in the era of precision medicine
E Fountzilas, AM Tsimberidou, HH Vo, R Kurzrock - Genome medicine, 2022 - Springer
Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …
unique molecular features that drive malignancies. Precision medicine has exploited next …
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a …
K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott… - The Lancet, 2022 - thelancet.com
Background Current standard of care for metastatic castration-sensitive prostate cancer
supplements androgen deprivation therapy with either docetaxel, second-generation …
supplements androgen deprivation therapy with either docetaxel, second-generation …
NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines
EM Schaeffer, S Srinivas, N Adra, Y An… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional …
prostate cancer diagnosis and include management options for localized, regional …
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …
Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and …
M Guckenberger, Y Lievens, AB Bouma… - The Lancet …, 2020 - thelancet.com
Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …
systemically metastasised disease. In the absence of randomised phase 3 trials, early …
Epidemiology and genomics of prostate cancer in Asian men
Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …
different continents. Asia is traditionally considered a low-incidence area, but the incidence …
[HTML][HTML] Preoperative and postoperative systemic therapy for operable non–small-cell lung cancer
Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …